# Acarix > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/acarix). ## Overview Acarix is a Swedish medical technology company built around the CADScor System, a noninvasive diagnostic platform used to assess the likelihood of coronary artery disease. The company’s business combines device sales, disposable patch sales, and market development for use in clinical settings, with activity centered in Europe and the United States. ## Products & services • CADScor System for noninvasive CAD assessment • Disposable patches used with the CADScor System • Diagnostic device sales to clinical customers • Market access and commercialization support - **CADScor System** (55%) — Noninvasive diagnostic system used to assess coronary artery disease risk. - **Disposable patches** (35%) — Single-use patches consumed with each CADScor test. - **Services and commercialization support** (10%) — Market access, training, and related support for adoption of the system. - CADScor System for noninvasive CAD assessment - Disposable patches used with the CADScor System - Diagnostic device sales to clinical customers - Market access and commercialization support ## Customers Acarix sells primarily to healthcare providers that evaluate patients with suspected coronary artery disease and need a noninvasive triage tool. Its customer base also includes hospitals, clinics, and channel partners that help place the system into clinical workflows, especially in markets where reimbursement and regulatory acceptance matter. - **Hospitals and cardiology departments** (primary) — Buy the CADScor System to support coronary artery disease assessment in clinical workflows - **Outpatient clinics and diagnostic centers** (secondary) — Use the system for noninvasive patient triage and repeat testing - **Distribution and channel partners** (secondary) — Help place the product in new markets and support adoption - Hospitals and cardiology departments evaluating chest-pain patients - Clinics and outpatient centers using noninvasive triage tools - Healthcare systems seeking faster CAD assessment workflows - Distribution and commercialization partners in target markets ## Geography Acarix’s disclosed sales activity spans Europe and the United States, with the U.S. highlighted as an important growth market in recent reporting. The company also has historical sales in Germany, Sweden, Austria, and other European markets, which makes reimbursement, regulatory approvals, and local clinical adoption important to the business model. - **United States** (57%) — Estimated from reported sales mix and U.S. commercialization focus - **Europe** (43%) — Estimated from reported sales mix in Germany, Sweden, and Austria - United States is a key commercial market for CADScor System adoption - Germany has been a meaningful European sales market - Sweden and Austria appear in reported sales disclosures - European market access depends on reimbursement and regulatory acceptance ## Strategy Acarix’s strategy centers on expanding acceptance of the CADScor System, especially in the U.S. market, while securing the financing needed to support commercialization. The company also emphasizes partnerships, regulatory progress, and broader clinical adoption to move the product into routine use. - **Expand U.S. commercialization** (short-term) — The U.S. market offers the largest near-term opportunity for system placements and patch sales - **Broaden market access and reimbursement** (medium-term) — Clinical adoption depends on approval, reimbursement, and inclusion in care pathways - **Secure financing for growth** (short-term) — Commercial rollout and product development require ongoing capital support - Expand adoption of CADScor System in the U.S. market - Use partnerships to widen clinical reach and distribution - Pursue regulatory and market access approvals in target countries - Support commercialization with financing and disciplined resource use ## Risks Acarix faces commercialization risk because adoption of a new medical device can take time and may not translate into sufficient revenue. The company is also exposed to financing, regulatory, competitive, and supply-chain risks typical of early-stage medtech businesses, with market acceptance and reimbursement being especially important. - **Market acceptance of CADScor System** [high] — Revenue depends on clinicians adopting a new diagnostic workflow and trusting the product - **Financing and going-concern risk** [critical] — Commercialization and development require external capital until the business scales - **Regulatory and reimbursement delays** [high] — Market launches may require approvals and payer acceptance before sales can scale - **Competition and obsolescence** [medium] — Alternative diagnostic tools could limit adoption if they are cheaper or more established - **Supply-chain and trade disruption** [medium] — Imported components and cross-border operations can be affected by tariffs or logistics issues - Slow market acceptance can delay revenue generation - Future launches may be delayed by regulatory or reimbursement hurdles - Financing risk remains important for ongoing operations - Competition and product obsolescence can pressure adoption - Supply-chain and trade disruptions can affect components and costs ## Accounting Acarix’s reporting is shaped by revenue recognition on device and patch sales, which are recognized when control passes to the customer, and by lease accounting for premises and vehicles. Investors should also watch estimates around going concern, impairment, and any judgments tied to development costs, since these can materially affect reported results in a small medtech company. - **Revenue recognition for device and patch sales** — Point-in-time recognition for goods - **Lease accounting (IFRS 16)** — Affects balance sheet leverage and operating expense presentation - **Going concern and financing assumptions** — Can materially affect classification and disclosure - **Development cost and impairment judgments** — Important for a small R&D-driven medtech company - Revenue is recognized on delivery for goods sold - Patch sales can create recurring revenue timing effects - Lease accounting affects right-of-use assets and liabilities - Going-concern judgments depend on financing assumptions - Development and impairment estimates can move reported equity --- *Last updated: 2026-08-11T04:04:50.640437+00:00*